DGRW vs XBI
WisdomTree US Quality Dividend Growth Fund vs SPDR S&P Biotech ETF
- • DGRW has the lower expense ratio at 0.28% vs 0.35% for XBI.
- • DGRW pays a higher dividend yield (1.24%).
Side-by-side metrics
| Metric | DGRW | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.28% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.24% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $16.93B | $10.92B |
YTD return | 11.01% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.78 | 1.01 |
P/E ratio | 24.10 | — |
Last price | $98.82 | $156.41 |
Inception | — | — |
Issuer | WisdomTree | State Street |
DGRW top holdings
| NVDA | NVIDIA Corp | 7.89% |
| MSFT | Microsoft Corp | 7.81% |
| AAPL | Apple Inc | 4.47% |
| KO | Coca-Cola Co | 3.24% |
| META | Meta Platforms Inc Class A | 3.15% |
| UNH | UnitedHealth Group Inc | 2.78% |
| HD | The Home Depot Inc | 2.54% |
| JNJ | Johnson & Johnson | 2.45% |
| ABBV | AbbVie Inc | 2.36% |
| XOM | ExxonMobil Holdings Corp | 2.12% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About DGRW
DGRW (WisdomTree US Quality Dividend Growth Fund) is Dividend-paying US large caps with quality and growth screens. Managed by WisdomTree, the fund carries $16.9B in assets under management, an expense ratio of 0.28%, a dividend yield of 1.24%. Its largest holding is NVIDIA Corp (NVDA), which represents 7.9% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 7.3%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.